Literature DB >> 28087068

Clinical development of hepatitis C virus host-targeting agents.

Mirjam B Zeisel1, Thomas F Baumert2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28087068      PMCID： PMC5323320          DOI： 10.1016/S0140-6736(17)30043-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

Authors:  Meike H van der Ree; J Marleen de Vree; Femke Stelma; Sophie Willemse; Marc van der Valk; Svend Rietdijk; Richard Molenkamp; Janke Schinkel; Ad C van Nuenen; Ulrich Beuers; Salah Hadi; Marten Harbers; Eva van der Veer; Kai Liu; John Grundy; Amy K Patick; Adam Pavlicek; Jacqueline Blem; Michael Huang; Paul Grint; Steven Neben; Neil W Gibson; Neeltje A Kootstra; Hendrik W Reesink
Journal:  Lancet       Date:  2017-01-11       Impact factor: 79.321

Review 2.  miR-122--a key factor and therapeutic target in liver disease.

Authors:  Simonetta Bandiera; Sébastien Pfeffer; Thomas F Baumert; Mirjam B Zeisel
Journal:  J Hepatol       Date:  2014-10-13       Impact factor: 25.083

3.  Curing chronic hepatitis C--the arc of a medical triumph.

Authors:  Raymond T Chung; Thomas F Baumert
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

4.  Hepatitis C Drugs: Is Next Generation the Last Generation?

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2016-08-30       Impact factor: 22.682

5.  In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

Authors:  Søren Ottosen; Todd B Parsley; Lu Yang; Karin Zeh; Leen-Jan van Doorn; Eva van der Veer; Anneke K Raney; Michael R Hodges; Amy K Patick
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

6.  Treatment of HCV infection by targeting microRNA.

Authors:  Harry L A Janssen; Hendrik W Reesink; Eric J Lawitz; Stefan Zeuzem; Maribel Rodriguez-Torres; Keyur Patel; Adriaan J van der Meer; Amy K Patick; Alice Chen; Yi Zhou; Robert Persson; Barney D King; Sakari Kauppinen; Arthur A Levin; Michael R Hodges
Journal:  N Engl J Med       Date:  2013-03-27       Impact factor: 91.245

7.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Peter Richardson; Jennifer Kramer
Journal:  Hepatology       Date:  2016-04-19       Impact factor: 17.425

8.  Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.

Authors:  Fei Xiao; Isabel Fofana; Christine Thumann; Laurent Mailly; Roxane Alles; Eric Robinet; Nicolas Meyer; Mickaël Schaeffer; François Habersetzer; Michel Doffoël; Pieter Leyssen; Johan Neyts; Mirjam B Zeisel; Thomas F Baumert
Journal:  Gut       Date:  2014-05-21       Impact factor: 23.059

9.  Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Authors:  Fei Xiao; Joachim Lupberger; Laurent Mailly; Garrick K Wilson; Philippe Aubert; François H T Duong; Diego Calabrese; Céline Leboeuf; Isabel Fofana; Christine Thumann; Simonetta Bandiera; Marc Lütgehetmann; Tassilo Volz; Christopher Davis; Helen J Harris; Christopher J Mee; Erika Girardi; Béatrice Chane-Woon-Ming; Maria Ericsson; Nicola Fletcher; Ralf Bartenschlager; Patrick Pessaux; Koen Vercauteren; Philip Meuleman; Pascal Villa; Lars Kaderali; Sébastien Pfeffer; Markus H Heim; Michel Neunlist; Mirjam B Zeisel; Maura Dandri; Jane A McKeating; Eric Robinet; Thomas F Baumert
Journal:  Nat Biotechnol       Date:  2015-03-23       Impact factor: 54.908

Review 10.  Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.

Authors:  Mirjam B Zeisel; Emilie Crouchet; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2015-11-02       Impact factor: 5.048
  10 in total
  10 in total

Review 1.  Progressing from Recurring Tissue Injury to Genomic Instability: A New Mechanism of Neutrophil Pathogenesis.

Authors:  Triet M Bui; Ronen Sumagin
Journal:  DNA Cell Biol       Date:  2019-06-12       Impact factor: 3.311

2.  MicroRNA 122 Affects both the Initiation and the Maintenance of Hepatitis C Virus Infections.

Authors:  Mamata Panigrahi; Patricia A Thibault; Joyce A Wilson
Journal:  J Virol       Date:  2021-12-15       Impact factor: 6.549

Review 3.  The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses.

Authors:  Carla Eller; Laura Heydmann; Che C Colpitts; Eloi R Verrier; Catherine Schuster; Thomas F Baumert
Journal:  Cell Mol Life Sci       Date:  2018-08-10       Impact factor: 9.207

4.  Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.

Authors:  Katharina Herzog; Simonetta Bandiera; Sophie Pernot; Catherine Fauvelle; Frank Jühling; Amélie Weiss; Anne Bull; Sarah C Durand; Béatrice Chane-Woon-Ming; Sébastien Pfeffer; Marion Mercey; Hervé Lerat; Jean-Christophe Meunier; Wolfgang Raffelsberger; Laurent Brino; Thomas F Baumert; Mirjam B Zeisel
Journal:  Gut       Date:  2019-05-10       Impact factor: 31.793

5.  Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.

Authors:  Eloi R Verrier; Amélie Weiss; Charlotte Bach; Laura Heydmann; Vincent Turon-Lagot; Arnaud Kopp; Houssein El Saghire; Emilie Crouchet; Patrick Pessaux; Thomas Garcia; Patrick Pale; Mirjam B Zeisel; Camille Sureau; Catherine Schuster; Laurent Brino; Thomas F Baumert
Journal:  Gut       Date:  2019-03-04       Impact factor: 31.793

Review 6.  Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

7.  In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

Authors:  Laurent Mailly; Florian Wrensch; Laura Heydmann; Catherine Fauvelle; Nicolas Brignon; Mirjam B Zeisel; Patrick Pessaux; Zhen-Yong Keck; Catherine Schuster; Thomas R Fuerst; Steven K H Foung; Thomas F Baumert
Journal:  Antiviral Res       Date:  2018-12-30       Impact factor: 10.103

Review 8.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883

Review 9.  The Role of the Liver-Specific microRNA, miRNA-122 in the HCV Replication Cycle.

Authors:  Rasika D Kunden; Juveriya Q Khan; Sarah Ghezelbash; Joyce A Wilson
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

Review 10.  miRNAs as Potential Biomarkers for Viral Hepatitis B and C.

Authors:  Dimitri Loureiro; Issam Tout; Stéphanie Narguet; Sabrina Menasria Benazzouz; Abdellah Mansouri; Tarik Asselah
Journal:  Viruses       Date:  2020-12-14       Impact factor: 5.818
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.